Bharat Parenterals Returns to Profit as Q2 Revenue Rises 111%

Bharat Parenterals Ltd reported Q2 FY27 revenue of ₹136.28 crore, up 110.9% year-on-year and 45.4% sequentially, while net profit reached ₹11.82 crore against a loss in the year-earlier quarter. The performance reflected growth at Inoxel Life Sciences, though standalone input-cost pressure and uneven licensing income remain important factors.

What did Bharat Parenterals report for Q2 FY27?

Bharat Parenterals reported a marked improvement in financial performance for the quarter ended September 30, 2026. Revenue was ₹136.28 crore, total income was ₹138.82 crore and expenditure stood at ₹124.83 crore. Profit before tax was ₹14.00 crore, while net profit was ₹11.82 crore.

The company returned to profitability after reporting a loss of ₹8.6 crore in the comparable quarter a year earlier, according to the earnings-call highlights. Operating profit margin expanded to 17.30% from 1.3% in Q2 FY26, while net profit margin reached 8.51%. Earnings per share stood at ₹17.15.

How did Inoxel Life Sciences support Bharat Parenterals' growth?

Inoxel Life Sciences was the largest contributor to EBITDA during the quarter, with revenue increasing 253% year-on-year and EBITDA margin reaching 33%. Its performance helped support the group-level turnaround and reflected operating leverage in its business model.

Inoxel generated ₹65.9 crore of revenue in the first half of FY27, close to its full-year FY26 revenue of ₹72.4 crore. However, Director of Strategy and Investor Relations Bahim Desai said a substantial part of this revenue continued to come from licensing and milestone payments. Such payments are linked to events including technology transfer, exhibit batches, stability data, filings and approvals, making quarterly revenue uneven.

The company maintained its FY27 guidance for Inoxel revenue growth of 35% to 45% and an EBITDA margin of 20% to 25%. Management did not revise the outlook before gaining visibility on the timing of licensing income in the second half and the pace of commercial supply.

What is the significance of Inoxel's first US commercial supply?

Inoxel began its first commercial supply to the United States market on October 20, moving the unit into recurring contract manufacturing activity. The product is an oral liquid manufactured under a CMO agreement, and the sponsor partner is a specialty generics company in the US market.

No supply revenue from this product was included in the Q2 FY27 numbers. Management said a second contract-manufacturing product could be commercialised within FY27 after US Food and Drug Administration approval. Inoxel has three identified revenue streams: licensing and milestone income, commercial manufacturing and profit share from products developed by the company once they enter the market.

Desai said Inoxel is working on 38 projects for 18 to 19 clients and signed 16 deals in the first half of FY27. The company targets 12 to 15 new deals annually and expects 10 to 12 signed contracts by the end of Q3 FY27. Upfront contract fees account for 10% or less of revenue, with the larger share recognised as projects meet milestones.

What pressures remain in Bharat Parenterals' standalone business?

Bharat Parenterals' standalone business faces margin pressure because input-material costs rose by about five percentage points of revenue in one quarter. This reduced gross margin to 35%, even as the consolidated business reported stronger operating profitability.

Management said a meaningful portion of the existing standalone order book had been priced before the recent increase in material costs. Margins may therefore remain under pressure until those orders are completed and newly priced orders are executed. Injectables remain the core standalone segment, accounting for about 45% to 50% of standalone revenue, followed by oral solids.

The company is also preparing for a European Union Good Manufacturing Practice inspection. Upgrades to its HVAC systems, quality management systems and quality-control laboratory have been completed, but management said the regulator had not yet confirmed an inspection date. The inspection is still expected during the current financial year.

What are Bharat Parenterals' development and balance-sheet priorities?

Bharat Parenterals is advancing products and facilities that could influence its medium-term operating profile. Management said scale-up of liposomal and extended-release injectables is nearly complete, with exhibit batches planned for November. Qualification work following installation of the liposomal skid has been completed, and management said results were in line with laboratory-scale outcomes.

For the 13 advanced-stage assets, management indicated that ANDA filings generally require six months of stability data, while 505(b)(2) NDAs require 12 months of real-time data. It expects most development assets to reach the market by FY30. Some ANDAs and a couple of 505(b)(2) NDAs may be filed in FY27, with potential launches in calendar 2028 or FY29.

The group reported cash from operations of ₹83.3 crore in H1 FY27 and a debt-to-equity ratio of 0.08 times. Verinium Bio Life Sciences' biologics facility remains pre-revenue, with construction targeted for completion in Q2 of calendar year 2028. The project represents a future capital and execution requirement rather than a current revenue contributor.

Conclusion

Bharat Parenterals' Q2 FY27 results showed a return to profit, supported by 110.9% revenue growth, higher operating margin and Inoxel's contribution. The start of US commercial supply adds a manufacturing revenue stream, while the low debt-to-equity ratio and H1 operating cash flow provide financial context for the group's development plans.

Investors will watch the timing of Inoxel licensing income, the ramp-up of commercial supplies and the completion of lower-priced standalone orders. Other disclosed milestones include the expected EU GMP inspection during FY27, planned product filings and the targeted Q2 calendar 2028 completion of the Verinium Bio Life Sciences facility.